Evidence map›Paper›PMID 41217888›Full record

ArticleJournal of neuromuscular diseases2026

Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry.

Yasemin Erbaş, Laurent Servais, Perry B Shieh, Natalie L Goedeker, Megan A Waldrop, Ryosuke Bo, Dheeraj Raju, Kamal Benguerba, Sandra P Reyna, David Wolff and 1 more

Abstract read
In one paragraph

Article in Journal of neuromuscular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yasemin ErbaşSMA Europe, Freiburg, Germany.ORCID 0000-0002-0187-0580
Laurent ServaisDepartment of Paediatrics, MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Perry B ShiehDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Natalie L GoedekerWashington University School of Medicine, St Louis, MO, USA.
Megan A WaldropNationwide Children's Hospital, Columbus, OH, USA.
Ryosuke BoKobe University Graduate School of Medicine, Kobe, Japan.
Dheeraj RajuNovartis Pharma AG, Basel, Switzerland.
Kamal BenguerbaNovartis Pharma AG, Basel, Switzerland.
Sandra P ReynaNovartis Pharma AG, Basel, Switzerland.
David WolffNovartis Pharma AG, Basel, Switzerland.
Richard S FinkelCenter for Experimental Neurotherapeutics, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-9351-7054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the safety and effectiveness of onasemnogene abeparvovec (OA) for 34 patients with spinal muscular atrophy (SMA) and tracheostomies enrolled in the RESTORE registry. Most patients (76.5%) received other SMA treatments before and/or after OA. Safety findings were consistent with OA's established profile. There were four fatalities, three caused by respiratory events unrelated to OA, one of unknown cause. Overall, patients exhibited positive motor outcomes, even in cases where the need for tracheostomy emerged after treatment. These real-world data support OA treatment for patients with SMA and tracheostomies and can inform future access, treatment, and care decisions.

Indexed as

Muscular Atrophy, SpinalTracheostomyChildChild, PreschoolFemaleGene Therapy AgentsHumansInfantMaleRecombinant Fusion ProteinsRegistriesSpinal Muscular Atrophies of ChildhoodTreatment Outcomeonasemnogene abeparvovecRecombinant Fusion Proteinsonasemnogene abeparvovecregistryrespiratoryspinal muscular atrophytracheostomyventilation support

Identifiers

PMID41217888
PMCPMC13434910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.